Depomed
21
0
0
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
4.8%
1 terminated/withdrawn out of 21 trials
95.0%
+8.5% vs industry average
62%
13 trials in Phase 3/4
84%
16 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea
Role: collaborator
Simulated Driving Performance, Daytime Sedation and Cognition in Healthy Volunteers Taking Gralise, Neurontin or Lyrica
Role: lead
Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute
Role: lead
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Role: lead
A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain
Role: collaborator
Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl
Role: lead
Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old
Role: collaborator
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Role: lead
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
Role: lead
Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures
Role: collaborator
Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints
Role: collaborator
Study of Gralise to Treat Fibromyalgia Patients
Role: collaborator
IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine
Role: collaborator
Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations
Role: lead
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Role: lead
Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Role: lead
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
Role: lead
Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.
Role: lead
Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy
Role: lead
Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Role: lead